Using full probability models to compute probabilities of actual interest to decision makers

International Journal of Technology Assessment in Health Care

Volumn 17, Issue 1, 2001, Pages 17-26

  Harrell Jr , Frank E ^a   Shih, Ya Chen Tina ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNITED BIOSOURCE CORPORATION   (United States)

Author keywords

Bayesian statistics; Decision analysis; Multiple endpoints

Indexed keywords

BAYES THEOREM; COST BENEFIT ANALYSIS; DECISION MAKING; MORTALITY; PROBABILITY; REVIEW; STATISTICAL MODEL;

ARTERIAL OCCLUSIVE DISEASES; BAYES THEOREM; CLINICAL TRIALS; CORONARY DISEASE; DECISION MAKING; EVIDENCE-BASED MEDICINE; HEALTH SERVICES RESEARCH; HUMANS; MODELS, STATISTICAL; NIFEDIPINE; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0035034745     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462301104034     Document Type: Review

References (19)

1. Decision making during a phase III randomized controlled trial
2. Placing trials in context using Bayesian analysis
3. An economic approach to clinical trial design and research priority-setting
4. Standing statistics right side up
5. Clinical trials and statistical verdicts: Probable grounds for appeal
6. Nifedipine: Dose-related increase in mortality in patients with coronary heart disease
7. Toward evidence-based medical statistics, I: The P value fallacy
8. Towards evidence-based medical statistics, II: The Bayes factor
9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
10. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
11. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 4,299 cases of suspected acute myocardial infarction
12. Selecting treatments: A decision theoretic approach
13. Bayes offers a "new" way to make sense of numbers
14. Nifedipine and mortality: Grave defects in the dossier
15. Probabilistic prediction in patient management and clinical trials
16. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials